RxDoctor Payments Data

Carol Cherry

Nurse Practitioner · Henderson, NVNPI 1366923096

Payments from drug & device makers

$1,370in general payments, 2019–2025

Across 45 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$503
  • Collegium Pharmaceutical, Inc.$205
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$156
  • Biohaven Pharmaceuticals, Inc.$125
  • Astellas Pharma US Inc$121
  • Biodelivery Sciences International, Inc.$56
  • plus $203 from 9 others

What the payments were for

  • Food & beverage$1,370100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,370 in reported general payments places this provider in the 75th percentile of 933 nurse practitioner providers in Nevada.

See all nurse practitioner providers in Nevada

Medicare billing

Part B allowed, 2024
$54,316
Medicare patients
79
Services billed
614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$29,749
Xtampza ErOxycodone Myristate34$22,861
Hysingla ErHydrocodone Bitartrate18$13,090
Oxycodone Hcl323$9,135
EntrestoSacubitril/Valsartan11$7,645
Chlorzoxazone17$3,039
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen52$2,544
Morphine Sulfate ErMorphine Sulfate66$2,301
Lidocaine37$2,031
Naloxone Hcl26$1,991
Pregabalin47$1,951
Celecoxib36$1,743
Gabapentin155$1,560
Albuterol Sulfate HfaAlbuterol Sulfate52$1,533
Ranolazine ErRanolazine11$1,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$205$22,86134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 933 nurse practitioner providers in Nevada.

Other nurse practitioner in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →